Sodium Iodide I123Solution

Sodium iodide (Na123I).
Sodium iodide (Na123I) [41927-88-2].
»Sodium Iodide I123Solution is a solution,suitable for oral or for intravenous administration,containing radioactive iodine (123I)processed in the form of Sodium Iodide,obtained from the bombardment of enriched tellurium 124with protons or of enriched tellurium 122with deuterons,or by the decay of xenon 123in such manner that it is carrier-free.
Sodium Iodide I123Solution contains not less than 90.0percent and not more than 110.0percent of the labeled amount of 123Ias iodide expressed in megabecquerels (microcuries or millicuries)per mLat the time indicated in the labeling.Other chemical forms of radioactivity do not exceed 5percent of the total radioactivity.The Solution may contain a preservative or stabilizer.
Packaging and storage— Preserve in single-dose or in multiple-dose containers that previously have been treated to prevent adsorption,if necessary.
Labeling— Label it to include the following:the time and date of calibration;the amount of 123Ias iodide expressed as total megabecquerels (microcuries or millicuries)per mLat the time of calibration;the name and quantity of any added preservative or stabilizer;a statement to indicate whether the contents are intended for oral or for intravenous use;the expiration date and time;and the statement “Caution—Radioactive Material.”The labeling indicates that in making dosage calculations,correction is to be made for radioactive decay,and also indicates that the radioactive half-life of 123Iis 13.2hours.
Radionuclide identification (see Radioactivity á821ñ) Its gamma-ray spectrum is identical to that of a specimen of 123Iof known purity that exhibits a major photoelectric peak having an energy of 0.159MeV.
Radionuclidic purity— Using a suitable counting assembly (see Selection of a Counting Assemblyunder Radioactivity á821ñ),determine the radionuclidic purity of the Solution:not less than 85.0%of the total radioactivity is present as I123.
Bacterial endotoxins á85ñ The limit of endotoxin content is not more than 175/VUSP Endotoxin Unit per mLof the Injection,when compared with the USP Endotoxin RS,in which Vis the maximum recommended total dose,in mL,at the expiration date or time.
pHá791ñ: between 7.5and 9.0.
Radiochemical purity— Place a measured volume of a solution,containing 100mg of potassium iodide,200mg of potassium iodate,and 1g of sodium bicarbonate in each 100mL,25mm from one end of a 25-×300-mm strip of chromatographic paper (see Chromatography á621ñ),and allow to dry.To the same area add a similar volume of appropriately diluted Solution such that it provides a count rate of about 20,000counts per minute,and allow to dry.Develop the chromatogram over a period of about 4hours by ascending chromatography,using dilute methanol (7in 10).Dry the chromatogram in air,and determine the radioactivity distribution by scanning with a suitable collimated radiation detector:the radioactivity of the iodide 123Iband is not less than 95.0%of the total radioactivity,and its RFvalue falls within ±5.0%of the value found for sodium iodide when determined under similar conditions.Confirmation of the identity of the iodide band is made by the addition to the suspected iodide band of 6drops of acidified hydrogen peroxide solution (prepared by adding 6drops of 1Nhydrochloric acid to 10mLof hydrogen peroxide solution)followed by the dropwise addition of starch TS:the development of a blue color indicates the presence of iodide.
Other requirements— Solution intended for intravenous use meets the requirements under Injections á1ñ,except that it may be distributed or dispensed prior to completion of the test for Sterility,the latter test being started on the day of final manufacture,and except that it is not subject to the recommendation on Volume in Container.
Assay for radioactivity— Using a suitable counting assembly (see Selection of a Counting Assemblyunder Radioactivity á821ñ),determine the radioactivity,in MBq (µCi)per mL,of Solution by use of a calibrated system as directed under Radioactivity á821ñ.
Auxiliary Information— Staff Liaison:Andrzej Wilk,Ph.D.,Senior Scientific Associate
Expert Committee:(RMI)Radiopharmaceuticals and Medical Imaging Agents
USP28–NF23Page 1033
Phone Number:1-301-816-8305